Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

被引：3
|
作者：
Bykova, Anastasia [1 ]
Abdullaev, Adhamjon [1 ]
Gusarova, Galina [1 ]
Chelysheva, Ekaterina [1 ]
Treglazova, Svetlana [1 ]
Smirnova, Svetlana [1 ]
Turkina, Anna G. [2 ]
机构：
[1] Healthcare Minist Russian Federat, Hematol Res Ctr, Fed State Budgetary Inst, Moscow, Russia
[2] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.5538.5538
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms
    Johnson, Toby
    Xu, Chun-fang
    Choueiri, Toni K.
    Deen, Keith C.
    Xue, Zhengyu
    Bartlett-Pandite, Arundathy N.
    Carpenter, Christopher
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] UGT1A1 GENE VARIANTS IN NEONATAL HYPERBILIRUBINEMIA
    Kumar, A.
    Tiwari, P. K.
    Bhutada, A.
    Agarwal, R.
    Raman, R.
    PEDIATRIC RESEARCH, 2010, 68 : 410 - 411
  • [33] Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms
    Motzer, R. J.
    Johnson, T.
    Choueiri, T. K.
    Deen, K. C.
    Xue, Z.
    Pandite, L. N.
    Carpenter, C.
    Xu, C. F.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2927 - 2928
  • [34] Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
    Panagopoulos, Periklis
    Maltezos, Efstathios
    Hatzakis, Angelos
    Paraskevis, Dimitrios
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2017, 10 : 205 - 208
  • [35] Application of pharmacogenetics: UGT1A1☆28 and nilotinib-induced unconjugated hyperbilirubinaemia in a patient with chronic myeloid leukaemia
    Chen, Sammy Pak-lam
    Poon, Wing-tat
    Mak, Chloe Miu
    Lam, Ching-wan
    Kwong, Yok-lam
    Chan, Albert Yan-wo
    Tam, Sidney
    PATHOLOGY, 2011, 43 (03) : 273 - 274
  • [36] Role of UGT1A1 mutation in fasting hyperbilirubinemia
    Ishihara, T
    Kaito, M
    Takeuchi, K
    Gabazza, EC
    Tanaka, Y
    Higuchi, K
    Ikoma, J
    Watanabe, S
    Sato, H
    Adachi, Y
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (06) : 678 - 682
  • [37] Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
    Amandito, Radhian
    Rohsiswatmo, Rinawati
    Carolina, Erica
    Maulida, Rizka
    Kresnawati, Windhi
    Malik, Amarila
    FRONTIERS IN PEDIATRICS, 2019, 7
  • [38] Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism
    Mobaraki, Sajedeh
    Nissen, Peter Henrik
    Donskov, Frede
    Wozniak, Agnieszka
    Van Herck, Yannick
    Coosemans, Lina
    van Nieuwenhuyse, Tine
    Lambrechts, Diether
    Bechter, Oliver
    Baldewijns, Marcella
    Roussel, Eduard
    Laenen, Annouschka
    Beuselinck, Benoit
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [39] Commentary: Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
    Heydari, Mohammad Reza
    Fardaei, Majid
    FRONTIERS IN PEDIATRICS, 2020, 7
  • [40] Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
    Xu, C-F
    Reck, B. H.
    Xue, Z.
    Huang, L.
    Baker, K. L.
    Chen, M.
    Chen, E. P.
    Ellens, H. E.
    Mooser, V. E.
    Cardon, L. R.
    Spraggs, C. F.
    Pandite, L.
    BRITISH JOURNAL OF CANCER, 2010, 102 (09) : 1371 - 1377
12345